MAP2K7 and cancer: Alternative non-intrinsic MEK-activating pathways, that is, those not associated with EGFR/RAS/RAF mutations nor with mutations to MEK itself, have also been identified in select cancers such as uveal melanoma, where mutations in the Ras-like domain of the GPCR Gq subunit GNAQ drive the transcriptional activation of MEK [84].